- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Royal Bank Of Canada Raises Sarepta Therapeutics Price Target
Analysts lift price objective on biotech company's stock to $19.00
Apr. 8, 2026 at 1:28pm
Got story updates? Submit your updates here. ›
Royal Bank Of Canada analysts have increased their price target on shares of Sarepta Therapeutics (NASDAQ:SRPT) from $18.00 to $19.00, while maintaining a 'sector perform' rating on the biotechnology company's stock.
Why it matters
This price target adjustment reflects the analysts' updated outlook on Sarepta Therapeutics, a leading developer of precision genetic medicines for rare neuromuscular diseases. The new $19.00 target suggests potential downside from the stock's previous close, though the 'sector perform' rating indicates the analysts see the shares as fairly valued at current levels.
The details
In their research report, the Royal Bank Of Canada analysts cited Sarepta's recent financial and operational performance as factors behind the price target increase. The company reported Q4 2025 results in late February that included revenue of $442.93 million, down 32.7% year-over-year. Sarepta has several exon-skipping therapies approved by the FDA for the treatment of Duchenne muscular dystrophy.
- The new $19.00 price target was issued on April 8, 2026.
- Sarepta Therapeutics reported Q4 2025 financial results on February 25, 2026.
The players
Royal Bank Of Canada
A major Canadian multinational investment bank and financial services company.
Sarepta Therapeutics
A biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases.
The takeaway
This price target adjustment by Royal Bank Of Canada analysts reflects the ongoing challenges and uncertainty facing Sarepta Therapeutics as it navigates the competitive rare disease drug market. While the company's therapies have found success, the analysts see the shares as fairly valued at current levels based on the latest financial and operational performance.
